Recent Updates
Recently added Catalysts

NBIP-01435

Phase 2

Congenital Adrenal Hyperplasia | Small Molecules | Endocrine |Neurocrine Biosciences, Inc.|Trials Updated: Sep 30, 2026

NBIP-01435 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Sep 2026

NBIP-01435 target and mechanism

Molecular targetCRF1
Target classReceptor
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

NBIP-01435 clinical trials

NBIP-01435 · 1 trial · 1 indication

Phase 2 1
NCT07850739Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)Congenital Adrenal Hyperplasia
NOT YET_RECRUITING36 Analytics
PHASE2NOT YET_RECRUITING
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
Congenital Adrenal HyperplasiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in A4 Level at Week 8
Baseline, Week 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: NBIP-01435EXPERIMENTALParticipants will receive NBIP-01435 administered once a week (QW) subcutaneously (SC) for a minimum of 8 weeks.
Part 2: NBIP-01435EXPERIMENTALParticipants will receive NBIP-01435 administered SC for a minimum of 8 weeks.

Interventions

NameTypeDescription
NBIP-01435DRUGNBIP-01435 will be administered per schedule specified in the arm description.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: * Medically confirmed diagnosis of classic 21-hydroxylase deficiency (21-OHD) CAH, based on standard, medically accepted criteria. * Stable glucocorticoid (GC) dose regimen for classic CAH for a minimum of 30 days before screening. * If treated with fludrocortisone, the dose...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 30, 2026NCT07850739NEW_TRIAL: changed
LOWSep 30, 2026NCT07850739NEW_TRIAL: changed

Frequently asked questions about NBIP-01435

What is NBIP-01435?

NBIP-01435 is an investigational small molecule developed by Neurocrine Biosciences, Inc. (ticker NBIX) for the treatment of classic congenital adrenal hyperplasia, an endocrine disorder. It is currently in Phase 2 clinical development and has not been approved by the FDA.

What is NBIP-01435 used for in congenital adrenal hyperplasia?

NBIP-01435 is being developed as a treatment for classic congenital adrenal hyperplasia in adults. It is an investigational therapy in Phase 2 testing, and its efficacy and safety in this indication have not yet been established through completed clinical trials.

What does NBIP-01435 target?

NBIP-01435 targets CRF1, the corticotropin-releasing factor type 1 receptor. CRF1 is a receptor target, and NBIP-01435 is a small molecule designed to act on it. This receptor is the molecular target under investigation in its clinical program.

Who is developing NBIP-01435?

NBIP-01435 is being developed by Neurocrine Biosciences, Inc., which trades under the ticker NBIX. The company is the sponsor of the clinical program evaluating this small molecule in congenital adrenal hyperplasia.

What phase is NBIP-01435 in?

NBIP-01435 is in Phase 2 clinical development. It is an investigational drug and is not FDA approved. The Phase 2 program is evaluating the drug in adult participants with classic congenital adrenal hyperplasia.

What clinical trials is NBIP-01435 in?

NBIP-01435 is being studied in one clinical trial, NCT07850739, titled a Phase 2 study of efficacy, safety, tolerability, and pharmacokinetics in adult participants with classic congenital adrenal hyperplasia. The trial is not yet recruiting, is controlled, and is planned to enroll 36 participants.